Cukurova University Faculty of Medicine Dept of Medical Oncology, Adana, Turkey.
Crit Rev Oncol Hematol. 2019 Apr;136:56-63. doi: 10.1016/j.critrevonc.2019.02.001. Epub 2019 Feb 10.
Bruton tyrosine kinase signaling (BTK) is critical step for B-cell development and immunoglobulin synthesis. Ibrutinib is an orally bioavailable bruton tyrosine kinase inhibitor (BTKi) and forms an irreversible covalent bound to BTK at the Cysteine-481 residue. Ibrutinib has been approved by FDA for the treatment of mantle cell lymphoma, chronic lymphocytic leukemia, Waldenstrom's macroglobulinemia, marginal zone lymphoma and chronic graft-versus-host disease in allogeneic stem cell transplantation. Ibrutinib is generally well tolerated drug with rapid and durable responses but has some side events. The most common side effects are diarrhea, upper respiratory tract infection, bleeding, fatigue and cardiac side effects. These events are generally mild (grade I-II). However atrial fibrillation (AF) and bleeding are important and may be grade III or higher side effects require strict monitoring. Here side effects of ibrutinib have been summarized and important considerations in the management of these adverse events have been reviewed.
布鲁顿酪氨酸激酶信号转导（BTK）是 B 细胞发育和免疫球蛋白合成的关键步骤。伊布替尼是一种口服生物利用度的布鲁顿酪氨酸激酶抑制剂（BTKi），可与 BTK 的半胱氨酸 481 残基形成不可逆的共价结合。伊布替尼已获 FDA 批准，用于治疗套细胞淋巴瘤、慢性淋巴细胞白血病、华氏巨球蛋白血症、边缘区淋巴瘤和异基因干细胞移植中的慢性移植物抗宿主病。伊布替尼通常具有良好的耐受性，起效迅速且持久，但也有一些副作用。最常见的副作用是腹泻、上呼吸道感染、出血、疲劳和心脏副作用。这些事件通常是轻微的（1-2 级）。然而，心房颤动（AF）和出血是重要的，可能是 3 级或更高的副作用，需要严格监测。本文总结了伊布替尼的副作用，并对这些不良反应的处理进行了重要的考虑。
